This commentary critically appraises the study by Li et al which pioneered the exploration of the triglyceride-glucose(TyG)index as a prognostic marker in hepatitis B virus-related advanced hepatocellular carcinoma pa...This commentary critically appraises the study by Li et al which pioneered the exploration of the triglyceride-glucose(TyG)index as a prognostic marker in hepatitis B virus-related advanced hepatocellular carcinoma patients undergoing combined camrelizumab and lenvatinib therapy.While we acknowledge the study’s clinical relevance in proposing an easily accessible metabolic biomarker,we delve into the mechanistic plausibility linking insulin resistance to immunotherapy response and angiogenic inhibition.We further critically examine the methodological limitations,including the retrospective design,the populationspecific TyG cut-off value,and unaddressed metabolic confounders.We highlight the imperative for future research to validate its utility across diverse etiologies and treatment settings,and to unravel the underlying immunometabolic pathways.展开更多
This editorial comments on a study by Zuo et al.The focus is on the efficacy of he-patic arterial infusion chemotherapy combined with camrelizumab and apatinib(the TRIPLET regimen),alongside microwave ablation therapy...This editorial comments on a study by Zuo et al.The focus is on the efficacy of he-patic arterial infusion chemotherapy combined with camrelizumab and apatinib(the TRIPLET regimen),alongside microwave ablation therapy,in treating advanced hepatocellular carcinoma(HCC).The potential application of this combination therapy for patients with advanced HCC is evaluated.展开更多
Programmed death receptor-1 inhibitors have significantly improved the prognosis of various malignancies.Nevertheless,hyperprogressive disease(HPD),recognized as a severe adverse reaction to immunotherapy,causes a sub...Programmed death receptor-1 inhibitors have significantly improved the prognosis of various malignancies.Nevertheless,hyperprogressive disease(HPD),recognized as a severe adverse reaction to immunotherapy,causes a substantial surge in tumor burden and notably shortens the survival of 4%-29%of patients.This article comprehensively reviews the controversies regarding the clinical definition of HPD,its cross-cancer epidemiological features(encompassing gastric cancer,non-small cell lung cancer,head and neck squamous cell carcinoma,etc.),and potential molecular mechanisms(such as MDM2/MDM4 gene amplification,EGFR mutations,and reprogramming of the immune microenvironment).It further delves into biomarker-based predictive models,targeted combination therapy strategies,and salvage treatment alternatives.Ultimately,it puts forward future directions,including the establishment of a multicenter HPD registry database and organoid predictive models,aiming to offer evidence-based guidance for clinical practice.展开更多
In their study,Han et al compared the efficacy of bevacizumab plus sindilizumab plus interventional therapy with that of lenvatinib plus sindilizumab plus interventional therapy for patients with intermediate and adva...In their study,Han et al compared the efficacy of bevacizumab plus sindilizumab plus interventional therapy with that of lenvatinib plus sindilizumab plus interventional therapy for patients with intermediate and advanced hepatocellular carcinoma.The triple therapy,which integrates interventional therapy,targeted therapy,and immunotherapy,has emerged as a promising research focus in the treatment of liver cancer.Consequently,it is of utmost significance to select an appropriate combination of interventional therapy,targeted therapy,and immunotherapy for patients suffering from intermediate and advanced liver cancer.展开更多
In the clinical diagnosis and treatment of liver tumors,the differential diagnosis between dual-phenotype hepatocellular carcinoma and intrahepatic cholangiocarcinoma has long been a challenging problem for clinicians...In the clinical diagnosis and treatment of liver tumors,the differential diagnosis between dual-phenotype hepatocellular carcinoma and intrahepatic cholangiocarcinoma has long been a challenging problem for clinicians.These two types of tumors not only exhibit overlapping pathological features but also have significantly different treatment strategies and prognoses.Misdiagnosis can directly affect patients'quality of life.Recently,a study published by Zhang et al has brought groundbreaking insights into this dilemma.Radiomics technology has demonstrated remarkable value in the differential diagnosis of these two diseases,opening up a new path for the precise diagnosis and treatment of liver tumors.展开更多
In this editorial,we review the article“Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carc...In this editorial,we review the article“Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma”.We specifically focused on whether transarterial chemoembolization combined with lenvatinib in combination with a programmed death 1 inhibitor could be used in patients with unresectable hepatocellular carcinoma.Since both transarterial chemoembolization as well as lenvatinib in combination with programmed death 1 inhibitors play an important role in the treatment of advanced liver cancer,but the combination of all three therapeutic approaches needs more research.展开更多
文摘This commentary critically appraises the study by Li et al which pioneered the exploration of the triglyceride-glucose(TyG)index as a prognostic marker in hepatitis B virus-related advanced hepatocellular carcinoma patients undergoing combined camrelizumab and lenvatinib therapy.While we acknowledge the study’s clinical relevance in proposing an easily accessible metabolic biomarker,we delve into the mechanistic plausibility linking insulin resistance to immunotherapy response and angiogenic inhibition.We further critically examine the methodological limitations,including the retrospective design,the populationspecific TyG cut-off value,and unaddressed metabolic confounders.We highlight the imperative for future research to validate its utility across diverse etiologies and treatment settings,and to unravel the underlying immunometabolic pathways.
文摘This editorial comments on a study by Zuo et al.The focus is on the efficacy of he-patic arterial infusion chemotherapy combined with camrelizumab and apatinib(the TRIPLET regimen),alongside microwave ablation therapy,in treating advanced hepatocellular carcinoma(HCC).The potential application of this combination therapy for patients with advanced HCC is evaluated.
文摘Programmed death receptor-1 inhibitors have significantly improved the prognosis of various malignancies.Nevertheless,hyperprogressive disease(HPD),recognized as a severe adverse reaction to immunotherapy,causes a substantial surge in tumor burden and notably shortens the survival of 4%-29%of patients.This article comprehensively reviews the controversies regarding the clinical definition of HPD,its cross-cancer epidemiological features(encompassing gastric cancer,non-small cell lung cancer,head and neck squamous cell carcinoma,etc.),and potential molecular mechanisms(such as MDM2/MDM4 gene amplification,EGFR mutations,and reprogramming of the immune microenvironment).It further delves into biomarker-based predictive models,targeted combination therapy strategies,and salvage treatment alternatives.Ultimately,it puts forward future directions,including the establishment of a multicenter HPD registry database and organoid predictive models,aiming to offer evidence-based guidance for clinical practice.
文摘In their study,Han et al compared the efficacy of bevacizumab plus sindilizumab plus interventional therapy with that of lenvatinib plus sindilizumab plus interventional therapy for patients with intermediate and advanced hepatocellular carcinoma.The triple therapy,which integrates interventional therapy,targeted therapy,and immunotherapy,has emerged as a promising research focus in the treatment of liver cancer.Consequently,it is of utmost significance to select an appropriate combination of interventional therapy,targeted therapy,and immunotherapy for patients suffering from intermediate and advanced liver cancer.
文摘In the clinical diagnosis and treatment of liver tumors,the differential diagnosis between dual-phenotype hepatocellular carcinoma and intrahepatic cholangiocarcinoma has long been a challenging problem for clinicians.These two types of tumors not only exhibit overlapping pathological features but also have significantly different treatment strategies and prognoses.Misdiagnosis can directly affect patients'quality of life.Recently,a study published by Zhang et al has brought groundbreaking insights into this dilemma.Radiomics technology has demonstrated remarkable value in the differential diagnosis of these two diseases,opening up a new path for the precise diagnosis and treatment of liver tumors.
文摘In this editorial,we review the article“Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma”.We specifically focused on whether transarterial chemoembolization combined with lenvatinib in combination with a programmed death 1 inhibitor could be used in patients with unresectable hepatocellular carcinoma.Since both transarterial chemoembolization as well as lenvatinib in combination with programmed death 1 inhibitors play an important role in the treatment of advanced liver cancer,but the combination of all three therapeutic approaches needs more research.
